This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
| INTRODUC TI ON
Atrial fibrillation (AF) is associated with hemostatic hypercoagulability that may increase the susceptibility for formation of intra-cardiac thrombi, which may subsequently lead to systemic thromboembolic events and cerebral emboli. [1] [2] [3] In these patients, and especially those with left atrial enlargement, most of these thrombi originate in the left atrial appendage (LAA). 4 Among patients referred for evaluation of emboli from a potential cardiogenic source, spontaneous echo contrast within the left atrium is the most common transesophageal echocardiographic (TEE) finding in the setting of present thrombus. [5] [6] [7] [8] [9] [10] In the case of planned cardioversion for AF patients not on anticoagulation, it is recommended that a TEE be obtained to confirm the absence of intra-cardiac thrombus prior to the procedure. Although a large randomized trial has shown that a negative TEE obviates the need for prolonged anticoagulation prior to cardioversion, it does not eliminate the presence of intra-cardiac thrombi, which may have embolized in entirety prior to TEE. 9, 11 In one article, even after negative TEE results, an embolic rate of approximately 1% after electrical cardioversion was reported. 9 The complex structure of the LAA, which is often multilobed with unpredictable projections, makes the complete exclusion of small thrombi impossible. 12 For instance, in a quantitative autopsy study of 500 healthy subjects, the LAA had two or more lobes in 80% of hearts. 13 Moreover, the exclusion of LAA clots with the use of TEE still mandates close interrogation for left ventricular and proximal aortic thrombi. 14 Thus, despite being widely used in the diagnosis of atrial thrombi, TEE has a number of inherent limitations. [14] [15] [16] [17] [18] Earlier studies proposed that hemostatic biomarkers of hypercoagulability, cardiac dysfunction, and pro-thrombotic systemic inflammation may be useful in identifying patients at highest thromboembolic risk.. [19] [20] [21] [22] [23] [24] [25] In fact, thrombus formation in the cardiac chambers is mainly due to blood stasis, leading to a fibrin-rich clot very similar to venous thrombi. [26] [27] [28] Considering the mechanism of clot formation, it is clear that patients with AF/flutter may have increased levels of D-dimer 21, 29 and up-regulated biomarkers of pro-thrombotic endothelial dysfunction. [30] [31] [32] However, the clinical role of hemostatic biomarker parameters as a supplemental approach in the exclusion/diagnostics of intra-cardiac thrombi remains to be determined. The aim of our study was to evaluate how the level of these biomarkers and D-dimer levels, a marker of cross-linked fibrin, may be useful in the risk assessment of cardiac thrombi in the context of current practice.
| PATIENTS AND ME THODS

| Study population
This was a prospective, single-center study. We approached patients who underwent transthoracic echocardiography (TTE) and TEE at the Division of Cardiology at Augusta University Medical Center to evaluate for cardiogenic sources of emboli between May 2007 and July 2011. Our recruitment was based on patient willingness to participate, with the consent of their treating physicians. TEE was requested for indications including AF, atrial flutter, and acute stroke of cryptogenic etiology. Exclusion criteria were any history of malignancy, chronic or acute inflammatory disease, systemic disease, connective tissue disease, autoimmune disease, pregnancy, any coagulation disorders, or thromboembolic events 60 days prior to being enrolled in the study.
Data on patient demographic characteristics, medical history, physical examination, clinical features, and routine hematologic blood tests were obtained from the patient chart, whereas TTE/TEE echo contrast and D-dimer data were collected prospectively. Anticoagulation therapy was started based on TEE results and CHADS 2 scores, as recommended in the AHA/ACC guidelines for the management of patients with AF. Cardioversion was successfully performed in 22 (76%) patients from 29 patients diagnosed with AF or atrial flutter without LAA thrombus. The study protocol was approved by the Institutional Review Board, and informed written consent was obtained from each patient prior to inclusion in the study.
| Hemostatic blood tests
Routine hematologic and biochemical blood tests were performed at the Augusta University Medical Center Core Laboratory. Levels of D-dimer were measured by means of the HemosIL D-Dimer latex assay (IACLTOP 700 analyzer; Instrumentation Laboratory). The detection limit of this assay was 20 ng/mL. Measurements were carried out by personnel unaware of the patients' identities or clinical status.
| Transesophageal echocardiography
Transesophageal echocardiography was performed with patients in the left lateral decubitus position with a SONOS 7500 and iE33 echocardiographic imaging system (Philips) equipped with a 5-MHz multiplane transducer. The peak emptying velocity of the LAA was measured. Transesophageal parameters were reinterpreted off line by two investigators, without knowledge of patients' characteristics.
The average values of five cardiac cycles were used for analysis.
| Statistics
The primary endpoint of the study was the presence or absence of left atrial thrombus as confirmed by TEE report. Any false negative TEE results would be recorded as a positive left atrial thrombus. All statistical analysis was performed using SAS 9.3, and statistical significance was assessed using an alpha level of 0.05. The results are given as mean ± standard deviation (SD) or frequencies and percentages where appropriate. Due to violations of assumptions of chi-square, t tests, and one-way ANOVA, nonparametric alternatives to these parametric tests were used. To examine differences in demographic and clinical variables between those with D-dimer levels <200 ng/mL and those with D-dimer levels ≥200 ng/mL, Fisher's exact tests and Wilcoxon rank sum tests were performed. The Pearson correlation was determined between age and D-dimer levels. A Kruskal-Wallis test was used to examine differences in the median D-dimer and white blood cell (WBC) count between atrial fibrillation, atrial flutter, and neither groups. Differences in clinical measures between those with and without an intra-cardiac clot among those with D-dimer levels ≥200 ng/mL were determined using the Wilcoxon rank sum test. Logistic regression was used to estimate a receiver operating characteristic (ROC) curve and the area under the ROC (AROC) for D-dimer, LAA velocity, left ventricular ejection fraction (LVEF), and leukocyte counts depending on LAA clot status.
| RE SULTS
| Clinical characteristics and usefulness of D-dimer in the exclusion of LAA thrombus
We enrolled 35 men and 25 women aged between 26 and 88 years (mean 63.2 ± 14 years). All patients were diagnosed with either AF or atrial flutter (59.3%) and acute stroke (45.7%), and referred to the TEE laboratory for a clinically indicated examination for intra-cardiac thrombi. Patients with acute stroke were initially diagnosed with a cryptogenic ischemic event by magnetic resonance imaging and/or CT of the brain. As TEE was the basis for thrombus presence or absence, one patient with acute stroke was excluded after enrollment due to thrombus detection by magnetic resonance angiography (MRA) and magnetic resonance imaging (MRI). After eligibility screening, all 59 of the remaining patients were involved in the study analysis. LAA thrombi were detected by TEE in seven patients (12%; five patients with AF, one patient with atrial flutter, and one patient with acute stroke), which was consistent with the clot prevalence reported by others. 33 At baseline, there were no significant differences in the plasma D-dimer levels between LAA thrombus-positive (836 ± 917 ng/mL) and thrombus-negative (563 ± 991 ng/mL) groups ( Figure 1A ), due to the wide distribution of D-dimer levels in the thrombus-negative group (20-5779 ng/mL). In our population, the optimal D-dimer cutoff point was selected to be 200 ng/mL ( Figure 1C ,D), the D-dimer level that maximizes the sensitivity and specificity. Using a cutoff value of D-dimer ≥200 ng/mL, the D-dimer assay had a 100% sensitivity and 26.9% specificity ( Figure 1B ), 100% negative predictive value (NPV), and 15.6% positive predictive value (PPV), and a level ≥200 ng/mL will be referred to as a "positive D-dimer test result." Groups with either a positive or negative D-dimer test result had comparable clinical characteristics, except for sex ( Table 1 ). Independent predictors of embolism, including diagnosis of ischemic stroke, hyperlipidemia or heart failure, LVEF, and LAA velocity, did not correlate with D-dimer elevation. The only demographic predictor that correlated with elevated D-dimer levels was decreased basophil count (P = .027; Table 2 ). Figure 2D ). An ROC curve analysis showed that for a cutoff point of <35%, the LVEF had 71% sensitivity, 73% specificity, 26% PPV, and 95% NPV ( Figure 2E ).To assess the usefulness of a noninvasive LVEF test for the diagnosis of cardiac thrombi, an ROC curve analysis was performed on LVEF values combined with a positive D-dimer test result ( Figure 2F ). The AUC curve for the combination of the LVEF test with a positive D-dimer was increased compared with the LVEF test alone (0.80 vs 0.72, P = .0264), suggesting that association of a low LVEF value and D-dimer ≥200 ng/mL may also serve as a noninvasive parameter for the risk of a thrombus.
| Usefulness of cardiac morphological markers in the exclusion of LAA thrombus
| Association of LAA thrombus with WBC count
Among all patients with a positive D-dimer test, patients with LAA thrombus were more likely to have an elevation of pro-inflammatory 
| D ISCUSS I ON
In this era of healthcare cost reduction combined with patient outcome improvement, the ability to harness the clinical utility of D-dimer, as well as other cost-effective and noninvasive blood tests, is paramount. Several authors have added information on D-dimer levels into clinical decision-making for patients with suspected deep venous thrombosis (DVT) and pulmonary embolism (PE). [34] [35] [36] Using this D-dimer information clinically has allowed emergency room physicians to discharge patients safely from the emergency department if they are a low clinical risk with a negative D-dimer level. One study has shown that in a low clinical risk group, the addition of a positive D-dimer level increases the likelihood of a positive CTA for PE to the same frequency as the high Wells score criteria group. 37 Separate from the clear diagnostic The addition of D-dimer and other risk factors will help to detect these patients. Identifying these patients is crucial, as it would alter their subsequent therapy from antiplatelet to anticoagulation, which is known to be much more effective in reducing subsequent thromboembolic events. 43 There were several limitations to this study that merit discus- No similar to that reported by other investigators. Third, though our data were essentially complete for our major values five patients with negative clot and the positive D-dimer level did not have a complete hematologic WBC profile, which could have obscured these results. Also, our cutoff value for the D-dimer assay may not apply to other individual laboratories that may have their own cutoff value based on the type of D-dimer analyzer used. Additionally, although intra-cardiac thrombus was correlated to levels of selected pro-inflammatory and pro-thrombotic subpopulation of circulating leukocytes, a relationship between thrombosis and systemic hemostasis is still unclear. Inflammation is not the only predictor of cardiac thrombus and cannot be used as a positive predictor for diagnosis. The data may be applicable only as exclusion criteria to supplement TEE findings or estimate potential risks for subjects who are not eligible for TEE.
| CON CLUS ION
D-dimer levels <200 ng/mL and LAA velocities >40 cm/s were strongly associated with the absence of intra-cardiac clots.
Individuals with plasma D-dimer greater than 200 ng/mL and LAA velocity <40 cm/s may be candidates for focused target organ imaging for evidence of prior thrombus. Pro-inflammatory and prothrombotic leukocyte indices were related to thrombus formation and may be used in combination with the positive D-dimer test and LVEF data as surrogate noninvasive parameters to help stratify risk of intra-cardiac thrombus. Further prospective studies of larger size are needed to validate our findings.
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